Related Experiment Video
Updated: Aug 14, 2026

Processing of Bronchoalveolar Lavage Fluid and Matched Blood for Alveolar Macrophage and CD4+ T-cell Immunophenotyping and HIV Reservoir Assessment
Published on: June 23, 2019
Pulmonary Sporothrix schenckii infection in a HIV positive child
Steven F J Callens1, Faustin Kitetele, Pauline Lukun
1Pediatric Hospital Kalembe Lembe, Kinshasa, Democratic Republic of the Congo. callens@email.unc.edu
Abstract:
Sporothrix schenckii is a ubiquitous fungus, causing mostly non life-threatening localized infections of the skin and subcutaneous tissues that can be treated with oral antifungal agents. Meningeal, pulmonary and osteoarticular dissemination occur mainly in immunosuppressed patients. Pulmonary sporotrichosis is rare and responds poorly to treatment. Cases of disseminated sporotrichosis have most frequently been reported in patients residing in South America and Asia, and have increasingly been reported in AIDS patients. The distribution and pathogenicity of S. schenckii in Sub-Saharan Africa is not well known. We report a case of invasive pulmonary sporotrichosis in an eleven year old HIV-infected boy in Kinshasa, Democratic Republic of the Congo, successfully treated with oral fluconazole.
Insights
Sporothrix schenckii can cause rare, severe lung infections, especially in immunocompromised individuals. This case highlights successful treatment of invasive pulmonary sporotrichosis in an HIV-infected child in Sub-Saharan Africa using oral fluconazole.
Area of Science:
- Medical Mycology
- Infectious Diseases
- Public Health in Africa
Background:
- Sporothrix schenckii typically causes localized skin infections, but disseminated disease, including pulmonary involvement, is a concern in immunocompromised patients.
- Pulmonary sporotrichosis is uncommon and often has a poor treatment response.
- The epidemiology of Sporothrix schenckii in Sub-Saharan Africa remains poorly understood.
Observation:
- A case of invasive pulmonary sporotrichosis is presented in an 11-year-old HIV-infected boy in Kinshasa, Democratic Republic of the Congo.
- The patient presented with a rare and severe manifestation of the fungal infection.
Findings:
- The invasive pulmonary sporotrichosis in this pediatric patient was successfully treated with oral fluconazole.
- This demonstrates a viable therapeutic option for a challenging clinical presentation.
Implications:
- This case expands the understanding of Sporothrix schenckii pathogenicity in Sub-Saharan Africa.
- Successful treatment with oral fluconazole offers a potential management strategy for similar cases in resource-limited settings.
- Highlights the importance of considering fungal infections in immunocompromised children presenting with respiratory symptoms.
Related Concept Videos
Cryptococcal Meningitis
Pulmonary Tuberculosis I
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
Pulmonary Tuberculosis IV
Several diagnostic approaches are used to detect TB. The conventional method is the Tuberculin Skin Test (TST), also known as the Mantoux test. However, this method has...
Pulmonary Tuberculosis II
Here is a detailed explanation of its pathophysiology:
Transmission: The process begins when a person inhales droplet nuclei containing M. tuberculosis. These are typically released into the air when an individual with pulmonary or...
Pulmonary Tuberculosis III
The first classification is based on the development of the disease, and it includes the following categories:
Sexually Transmitted Infections